A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
Status:
Completed
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
The primary purpose of this research study is to evaluate how safe, how well tolerated and
how effective a range of doses of L-DOS47 in patients with non-squamous non-small cell lung
cancer when given as a monotherapy.